3.10
+0.1305(+4.39%)
Currency In USD
| Previous Close | 2.97 |
| Open | 2.94 |
| Day High | 3.11 |
| Day Low | 2.94 |
| 52-Week High | 4.6 |
| 52-Week Low | 2.75 |
| Volume | 666,911 |
| Average Volume | 403,754 |
| Market Cap | 261.88M |
| PE | -1.5 |
| EPS | -2.07 |
| Moving Average 50 Days | 3.21 |
| Moving Average 200 Days | 3.51 |
| Change | 0.13 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $102.19 as of February 05, 2025 at a share price of $3.101. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $451.31 as of February 05, 2025 at a share price of $3.101.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 13, 2025 12:00 PM GMT
Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales The Regimen, i
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today annou
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
GlobeNewswire Inc.
Dec 16, 2024 10:00 AM GMT
BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to